CTOs on the Move


 
QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.qiagen.com
  • 19300 Germantown Road
    Germantown, MD USA 20874
  • Phone: 800.426.8157

Executives

Name Title Contact Details

Similar Companies

Friendship Health and Rehab Center

Friendship Health and Rehab Center is a Roanoke, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fog Pharmaceuticals

FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered `undruggable`.

DTx Pharma

DTx Pharma is a San Diego based startup with a novel technology for delivery of RNA medicines.

Freenome

Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent cancer. We have pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw. By combining deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, we are developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science. Our recent $270 Million Series C brings our financing to over $500 million from investors, including; Bain Capital, Perceptive Advisors, RA Capital, Polaris Partners, Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., GV (formerly Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society`s BrightEdge Ventures, Data Collective Venture Capital, Novartis and Verily Life Sciences.